Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease

Approximately 20% of vascular patients treated with acetyl salicylic acid (i.e., aspirin) demonstrate less than expected platelet inhibition – putting them at a four-fold increased risk of adverse cardiovascular events. Low-dose rivaroxaban (2.5 mg twice daily) in combination with low-dose aspirin h...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Hamzah Khan, Mariya Popkov, Shubha Jain, Niousha Djahanpour, Muzammil H. Syed, Margaret L. Rand, John Eikelboom, C. David Mazer, Mohammed Al-Omran, Rawand Abdin, Mohammad Qadura
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2022-08-01
Sarja:Frontiers in Cardiovascular Medicine
Aiheet:
rivaroxaban
aspirin
antiplatelet
non-sensitivity
vascular
Linkit:https://www.frontiersin.org/articles/10.3389/fcvm.2022.912114/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.912114/full

Samankaltaisia teoksia